Thermo Fisher Scientific (TMO) Expected to Announce Earnings on Thursday

Thermo Fisher Scientific (NYSE:TMO) will likely be announcing its Q4 2025 results before the market opens on Thursday, January 29th. Analysts expect Thermo Fisher Scientific to post earnings of $6.44 per share and revenue of $11.9519 billion for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, January 29, 2026 at 8:30 AM ET.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the company posted $5.28 earnings per share. On average, analysts expect Thermo Fisher Scientific to post $23 EPS for the current fiscal year and $26 EPS for the next fiscal year.

Thermo Fisher Scientific Stock Up 2.8%

Shares of Thermo Fisher Scientific stock opened at $636.26 on Thursday. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The business has a 50-day moving average price of $588.78 and a 200 day moving average price of $528.67. Thermo Fisher Scientific has a fifty-two week low of $385.46 and a fifty-two week high of $637.98. The firm has a market cap of $239.05 billion, a P/E ratio of 36.76, a P/E/G ratio of 4.07 and a beta of 0.91.

Thermo Fisher Scientific announced that its Board of Directors has authorized a share buyback program on Thursday, November 6th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, January 15th. Investors of record on Monday, December 15th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

Insider Activity

In other Thermo Fisher Scientific news, COO Michel Lagarde sold 22,046 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $563.56, for a total value of $12,424,243.76. Following the completion of the sale, the chief operating officer directly owned 84,117 shares in the company, valued at $47,404,976.52. This represents a 20.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Lisa P. Britt sold 1,058 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total value of $622,379.08. Following the transaction, the vice president owned 13,087 shares in the company, valued at approximately $7,698,558.62. This trade represents a 7.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 149,271 shares of company stock valued at $86,507,282 over the last 90 days. Corporate insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

Hedge funds have recently made changes to their positions in the business. JPL Wealth Management LLC bought a new stake in shares of Thermo Fisher Scientific in the 3rd quarter worth approximately $28,000. Osterweis Capital Management Inc. increased its holdings in shares of Thermo Fisher Scientific by 151.4% in the third quarter. Osterweis Capital Management Inc. now owns 88 shares of the medical research company’s stock valued at $43,000 after buying an additional 53 shares in the last quarter. Wealth Watch Advisors INC acquired a new stake in shares of Thermo Fisher Scientific during the 3rd quarter valued at $44,000. Palisade Asset Management LLC bought a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth $46,000. Finally, Turning Point Benefit Group Inc. acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth $53,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on TMO shares. Evercore ISI reaffirmed an “outperform” rating and set a $650.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. Barclays lifted their price objective on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Friday, January 9th. KeyCorp raised Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price target on the stock in a report on Sunday, December 7th. Finally, Leerink Partners increased their price objective on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a report on Wednesday, October 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $625.47.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.